Olmesartan Medoxomil Hydrochlorothiazide Tablet
Description
OLMEROOT-H
Olmesartan Medoxomil 20 mg and Hydrochlorothiazide 12.5 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Olmesartan Medoxomil IP — 20 mg
Hydrochlorothiazide IP — 12.5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
OLMEROOT-H is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 20 mg and Hydrochlorothiazide 12.5 mg, formulated for the effective management of hypertension and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the diuretic action of Hydrochlorothiazide, resulting in superior antihypertensive efficacy and enhanced target organ protection.
Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Hydrochlorothiazide is a thiazide diuretic that increases sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and enhances the antihypertensive effect of Olmesartan.
OLMEROOT-H is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, obesity, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy.
Technical Knowledge of Olmesartan Medoxomil and Hydrochlorothiazide
Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling.
Hydrochlorothiazide acts on the distal convoluted tubule of the nephron by inhibiting sodium-chloride reabsorption, resulting in increased urinary excretion of sodium, chloride, and water. Long-term therapy reduces peripheral vascular resistance and contributes to sustained blood pressure reduction.
The combination of Olmesartan and Hydrochlorothiazide provides complementary antihypertensive mechanisms with additional cardiovascular and renal protective benefits.
Mechanism of Action
Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues.
Hydrochlorothiazide promotes sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and enhances antihypertensive efficacy.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides sustained 24-hour blood pressure control
Supports cardiovascular and renal protection
Reduces peripheral vascular resistance
Helps control fluid-related hypertension
Improves overall blood pressure control compared with monotherapy
Suitable for long-term hypertension management under medical supervision
Clinical Applications
OLMEROOT-H is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with obesity, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction.
Facts About Olmesartan Medoxomil and Hydrochlorothiazide
Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Hydrochlorothiazide is a well-established thiazide diuretic that has been extensively studied in hypertension management and cardiovascular outcome trials. The combination is widely recommended for patients requiring dual antihypertensive therapy and improved blood pressure control.
Key Facts
ARB and thiazide diuretic combination therapy
Olmesartan Medoxomil 20 mg for vascular and renal protection
Hydrochlorothiazide 12.5 mg for effective diuretic support
Provides sustained 24-hour antihypertensive action
Effective in hypertension requiring combination therapy
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
OLMEROOT-H is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose OLMEROOT-H for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 20 mg and Hydrochlorothiazide 12.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
OLMEROOT-H from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Hydrochlorothiazide formulation.
